Provided by Tiger Trade Technology Pte. Ltd.

Oramed Pharmaceuticals

3.43
+0.02000.59%
Post-market: 3.450.0200+0.58%19:08 EST
Volume:164.32K
Turnover:565.66K
Market Cap:136.52M
PE:3.34
High:3.49
Open:3.40
Low:3.36
Close:3.41
52wk High:3.71
52wk Low:1.82
Shares:39.80M
Float Shares:32.56M
Volume Ratio:0.97
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.03
EPS(LYR):-0.4800
ROE:24.48%
ROA:-4.22%
PB:0.67
PE(LYR):-7.15

Loading ...

Company Profile

Company Name:
Oramed Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2002
Employees:
4
Office Location:
1185 Avenue of the Americas,Third Floor,New York,New York,United States
Zip Code:
10036
Fax:
- -
Introduction:
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Directors

Name
Position
Nadav Kidron
President, Chief Executive Officer, Director and Chairman
Miriam Kidron
Chief Scientific Officer and Director
Arie Mayer
Director
Benjamin Shapiro
Director
Daniel Aghion
Director
Yehuda Reznick
Director

Shareholders

Name
Position
Nadav Kidron
President, Chief Executive Officer, Director and Chairman
Avraham Gabay
Chief Financial Officer, Treasurer and Secretary
Joshua Hexter
Chief Operating and Business Officer
Miriam Kidron
Chief Scientific Officer and Director